Mani Foroohar, M.D.

Mani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines.

Dr. Foroohar joined Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Dr. Foroohar co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.

Dr. Foroohar holds a B.S. from UCLA, an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, and an MBA from Columbia.